Speed Was Key for Moderna in Making Covid Vaccine, Says Co-founder

The transcript discusses the development of a vaccine during the early stages of the pandemic, focusing on the speed advantage of Moderna's platform. It highlights the challenges faced by Moderna, a relatively small company, in gaining recognition and support from the U.S. government. The partnership with NIH was crucial in testing the vaccine quickly. The transcript also covers the global demand for the vaccine and the legal constraints that prevented unauthorized distribution, emphasizing the careful governance of the vaccine supply.

What was the role of the NIH in the vaccine development process for Moderna?

Why was it illegal for Moderna to distribute vaccines during the early stages of the pandemic?